# Immunovant, Inc.: overview

IMVT · Nasdaq · CIK 1764013 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/imvt.md) · [Financials](/companies/imvt/financials.md) · [Filings](/companies/imvt/filings.md) · [Insiders](/companies/imvt/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.74)](/filings/0001764013-25-000149.md) | [(0.76)](/filings/0001764013-26-000011.md) | not reported | [(0.71)](/filings/0001764013-26-000101.md) | [(0.73)](/filings/0001764013-25-000149.md) | [(0.61)](/filings/0001764013-26-000011.md) | not reported | [(0.75)](/filings/0001764013-26-000101.md) |
| Free cash flow | $m | [(88.8) d](/filings/0001764013-25-000149.md) | [(101) d](/filings/0001764013-26-000011.md) | [(111) d](/filings/0001764013-26-000064.md) | [(117)](/filings/0001764013-26-000101.md) | [(103) d](/filings/0001764013-25-000149.md) | [(92.3) d](/filings/0001764013-26-000011.md) | [(95.1) d](/filings/0001764013-26-000064.md) | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.43)](/filings/0001764013-23-000065.md) | [(1.71)](/filings/0001764013-25-000092.md) | [(1.88)](/filings/0001764013-26-000064.md) | [(2.73)](/filings/0001764013-26-000064.md) | [(2.77)](/filings/0001764013-26-000064.md) |
| Free cash flow | $m | [(106)](/filings/0001764013-23-000065.md) | [(188)](/filings/0001764013-25-000092.md) | [(215)](/filings/0001764013-26-000064.md) | [(377)](/filings/0001764013-26-000064.md) | [(407)](/filings/0001764013-26-000064.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imvt/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-21 | [Stout Jay S](/insiders/1702969.md) | Chief Technology Officer, Officer | Sale (S) | 2,595 | $28.94 | $75.1k | [Form 4](/filings/0001764013-26-000114.md) |
| 2025-12-12 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 16,666,666 | $21.00 | $350.0m | [Form 4](/filings/0001140361-25-045409.md) |
| 2025-01-13 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 16,845,010 | $20.00 | $336.9m | [Form 4](/filings/0001140361-25-001188.md) |
| 2023-10-02 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 1,526,316 | $38.00 | $58.0m | [Form 4](/filings/0001140361-23-046976.md) |
| 2022-10-06 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 416,667 | $6.00 | $2.5m | [Form 4](/filings/0001140361-22-036652.md) |
| 2020-09-04 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 380,000 | $33.00 | $12.5m | [Form 4](/filings/0001104659-20-102701.md) |
| 2020-04-16 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 1,034,483 | $14.50 | $15.0m | [Form 4](/filings/0001104659-20-048301.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $623.7m | 16,186,469 |  | Reduced −761,419 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $359.9m | 9,341,151 |  | Reduced −2,185,820 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $276.7m | 7,180,897 |  | Added +606,400 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $223.7m | 5,805,000 |  | Added +4,259,000 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $209.4m | 5,435,220 |  | Reduced −22,661 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $177.9m | 4,617,005 |  | Added +79,076 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $174.7m | 4,534,833 |  | Added +657,956 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $171.8m | 4,457,988 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $150.7m | 3,910,509 |  | Added +205,604 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $140.2m | 3,638,681 |  | Added +18,631 |

## Recent filings

[All 648 filings](/companies/imvt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-03 | 17:05 ET | [8-K](/filings/0001764013-26-000106.md) | 5.07 Shareholder vote results | 0001764013-26-000106 |
| 2026-08-06 | 07:29 ET | [10-Q](/filings/0001764013-26-000101.md) | Quarterly report, period 2026-06-30 | 0001764013-26-000101 |
| 2026-08-06 | 07:15 ET | [8-K](/filings/0001764013-26-000100.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001764013-26-000100 |
| 2026-07-22 | 16:10 ET | [DEF 14A](/filings/0001764013-26-000092.md) | Proxy statement, period 2026-09-02 | 0001764013-26-000092 |
| 2026-05-20 | 07:28 ET | [10-K](/filings/0001764013-26-000064.md) | Annual report, period 2026-03-31 | 0001764013-26-000064 |
| 2026-05-20 | 07:14 ET | [8-K](/filings/0001764013-26-000062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001764013-26-000062 |
| 2026-02-06 | 07:24 ET | [10-Q](/filings/0001764013-26-000011.md) | Quarterly report, period 2025-12-31 | 0001764013-26-000011 |
| 2026-02-06 | 07:16 ET | [8-K](/filings/0001764013-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001764013-26-000010 |
| 2025-12-12 | 17:20 ET | [SCHEDULE 13D/A](/filings/0001140361-25-045411.md) | Ownership report, active investor, amended | 0001140361-25-045411 |
| 2025-12-12 | 16:15 ET | [8-K](/filings/0001193125-25-317577.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-317577 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001764013-26-000064.md), filed May 20, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1764013
- Tickers: IMVT
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:48 ET. No prices; not investment advice.